Arla Foods secures FDA approval for use of whey protein hydrolysates

The FDA agreed that four ingredients in the company’s Peptigen and Lacprodan ranges meet the definition of peptones in the US Code of Federal Regulations

Arla Foods Ingredients has secured US Food & Drug Administration approval for the use of whey protein hydrolysates that support allergy management and gut comfort in infant formula.

The FDA agreed that four ingredients in the company’s Peptigen and Lacprodan ranges meet the definition of peptones in the US Code of Federal Regulations. As such, they are permitted for use in early-life nutrition.

Anders Steen Jørgensen, Head of Arla Foods Ingredients’ Pediatric Business Unit, said: “We have over 30 years’ experience in developing and producing safe, high-quality whey protein hydrolysates for the infant formula market at our state-of-the-art manufacturing facilities. Our strategy is to ensure these scientifically backed ingredients are available all over the world. We are delighted that US infant formula manufacturers can now use four of our hydrolysates in infant nutrition products targeting cow’s milk allergy management or reduction of gut discomfort.”

It is estimated that 2-3 per cent of infants in the US now suffer from cow’s milk allergy. In most cases where breastfeeding is not possible, hydrolyzed formulas backed by clinical proof of efficacy are recommended for them.